In order to aid clinicians in the management of IRIS, we review the epidemiology, clinical features, and treatment options for the common infectious manifestations of IRIS. Additionally, manifestations associated with significant morbidity and mortality, such as CMV-associated immune recovery vitritis (IRV) or immune recovery uveitis (IRU), are also reviewed. Treatment options and their evidence are presented. Until disease specific guidelines are developed for IRIS, therapy should be based on exist- [4, 6, 7, 10, 11, 26, 30-32, 41, 43, 45] Rheumatoid arthritis [29] Systemic lupus erythematosus (SLE) [91] Graves disease [92] , Autoimmune thyroid disease [93] Mycobacterium avium complex [4, 5, 23, 31, [94] [95] [96] Sarcoidosis & granulomatous reactions [20, 97] Other mycobacteria [4, 56, 57, 98, 99] Tattoo ink [100] Cytomegalovirus [4, 33, 61, 63] AIDS-related lymphoma [ [112] Molluscum contagiosum & genital warts [32] Sinusitis [113] Folliculitis [114, 115] ing evidence and individualized according to the severity of presentation.